Compositions for treating amyloidosis
AssigneeProthena Biosciences Limited
InventorsGENE G. KINNEY, SPENCER D. GUTHRIE, MARTIN KOLLER
Life of this patent
Estimating the term…
Abstract
Antibody formulations and methods useful for treatment of peripheral neuropathy in patients with AL amyloidosis.
Claims128
A method of treating a patient with peripheral neuropathy associated with AL amyloidosis, comprising administering an effective dosage of an antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662), thereby improving the neuropathy in the patient.
A method of independently treating peripheral neuropathy in a patient with AL amyloidosis, comprising administering an effective dosage of an antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662), wherein:
- (a) the patient presents with peripheral neuropathy;
- (b) the patient has not shown any cardiac response to such dosage when previously administered;
- (c) the patient has not shown any renal response to such dosage when previously administered;
- (d) the patient previously received treatment with a different agent that did not affect the patient's peripheral neuropathy;
- and/or
- (e) the patient is receiving treatment with a different agent that does not affect the patient's peripheral neuropathy.
An antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662) for use in a method of treating a patient with peripheral neuropathy associated with AL amyloidosis.
An antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662) for use in a method independently treating peripheral neuropathy in a patient with AL amyloidosis, wherein:
- (a) the patient presents with peripheral neuropathy;
- (b) the patient has not shown any cardiac response to such dosage when previously administered;
- (c) the patient has not shown any renal response to such dosage when previously administered;
- (d) the patient previously received treatment with a different agent that did not affect the patient's peripheral neuropathy;
- and/or
- (e) the patient is receiving treatment with a different agent that does not affect the patient's peripheral neuropathy.
Use of an antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662) in a method of treating a patient with peripheral neuropathy associated with AL amyloidosis.
Use of an antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662) for independently treating peripheral neuropathy in a patient with AL amyloidosis, wherein:
- (a) the patient presents with peripheral neuropathy;
- (b) the patient has not shown any cardiac response to such dosage when previously administered;
- (c) the patient has not shown any renal response to such dosage when previously administered;
- (d) the patient previously received treatment with a different agent that did not affect the patient's peripheral neuropathy;
- and/or
- (e) the patient is receiving treatment with a different agent that does not affect the patient's peripheral neuropathy.
Use of an antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662) in the manufacture of a medicament for treating a patient with peripheral neuropathy associated with AL amyloidosis.
Use of an antibody which competes for binding to human amyloid A peptide with antibody 2A4 (ATCC Accession Number 9662) in the manufacture of a medicament for independently treating peripheral neuropathy in a patient with AL amyloidosis, wherein:
- (a) the patient presents with peripheral neuropathy;
- (b) the patient has not shown any cardiac response to such dosage when previously administered;
- (c) the patient has not shown any renal response to such dosage when previously administered;
- (d) the patient previously received treatment with a different agent that did not affect the patient's peripheral neuropathy;
- and/or
- (e) the patient is receiving treatment with a different agent that does not affect the patient's peripheral neuropathy.
Dependencies are inferred from the claim text.